Microbion Corporation today announced positive topline safety and efficacy results from its recently completed Phase 2 study of topical pravibismane for diabetic foot ulcer infections (DFI). The study ...

Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed a revolutionary injectable granular ...

Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed a revolutionary injectable granular filler that could transform the way diabetic wounds are treated, potentially ...

Loss of feeling to the foot puts them at high risk for injury to the feet and people may not feel their foot was injured ...

The Terasaki Institute has created an injectable, porous dermal filler made from biocompatible materials that enhances ...

Diabetes-related amputations represent one of the most severe complications of the disease, affecting thousands of patients ...

"This technology marks a major breakthrough in wound care and management ... "This innovative approach to treating diabetic foot ulcers represents exactly the kind of clinically translational ...

In 2023, the market for negative pressure wound therapy is projected to be worth USD 6.5 billion. By 2033, the market is ...

Diabetes silently affects millions globally, often progressing without obvious symptoms until it creates life-altering complications. Among the most s ...

ON101 is more effective than absorbent dressings for the treatment of diabetic foot ulcers among patients with risk factors that delay wound healing.

On World Diabetes Day, experts emphasize the importance of identifying early signs of diabetic foot complications, which can ...